Testosterone replacement therapy and hospitalization rates in men with COPD

Jacques Baillargeon, Randall Urban, Wei Zhang, Mohammed Fathi Zaiden, Zulqarnain Javed, Melinda Sheffield-Moore, Yong Fang Kuo, Gulshan Sharma

Research output: Contribution to journalArticle

Abstract

Testosterone deficiency is common in men with chronic obstructive pulmonary disease (COPD) and may exacerbate their condition. Research suggests that testosterone replacement therapy (TRT) may have a beneficial effect on respiratory outcomes in men with COPD. To date, however, no large-scale nationally representative studies have examined this association. The objective of the study was to assess whether TRT reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD. We conducted two retrospective cohort studies. First, using the Clinformatics Data Mart-a database of one of the largest commercially insured populations in the United States-we examined 450 men, aged 40-63 years, with COPD who initiated TRT between 2005 and 2014. Second, using the national 5% Medicare database, we examined 253 men, aged ≥66 years, with COPD who initiated TRT between 2008 and 2013. We used difference-in-differences (DID) statistical modeling to compare pre- versus post-respiratory hospitalization rates in TRT users versus matched TRT nonusers over a parallel time period. DID analyses showed that TRT users had a greater relative decrease in respiratory hospitalizations compared with nonusers. Specifically, middle-aged TRT users had a 4.2% greater decrease in respiratory hospitalizations compared with nonusers (-2.4 decrease vs. 1.8 increase; p = 0.03); and older TRT users had a 9.1% greater decrease in respiratory hospitalizations compared with nonusers (-0.8 decrease vs. 8.3 increase; p = 0.04). These findings suggest that TRT may slow disease progression in patients with COPD. Future studies should examine this association in larger cohorts of patients, with particular attention to specific biological pathways.

LanguageEnglish (US)
JournalChronic respiratory disease
Volume16
DOIs
StatePublished - Jan 1 2019

Fingerprint

Chronic Obstructive Pulmonary Disease
Testosterone
Hospitalization
Therapeutics
Databases
Respiratory Rate
Medicare
Disease Progression
Cohort Studies
Retrospective Studies

Keywords

  • androgen therapy
  • chronic obstructive pulmonary disease
  • hospitalization
  • Testosterone replacement therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Testosterone replacement therapy and hospitalization rates in men with COPD. / Baillargeon, Jacques; Urban, Randall; Zhang, Wei; Zaiden, Mohammed Fathi; Javed, Zulqarnain; Sheffield-Moore, Melinda; Kuo, Yong Fang; Sharma, Gulshan.

In: Chronic respiratory disease, Vol. 16, 01.01.2019.

Research output: Contribution to journalArticle

@article{7e3a328699724216a3b961c8f6ae5b61,
title = "Testosterone replacement therapy and hospitalization rates in men with COPD",
abstract = "Testosterone deficiency is common in men with chronic obstructive pulmonary disease (COPD) and may exacerbate their condition. Research suggests that testosterone replacement therapy (TRT) may have a beneficial effect on respiratory outcomes in men with COPD. To date, however, no large-scale nationally representative studies have examined this association. The objective of the study was to assess whether TRT reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD. We conducted two retrospective cohort studies. First, using the Clinformatics Data Mart-a database of one of the largest commercially insured populations in the United States-we examined 450 men, aged 40-63 years, with COPD who initiated TRT between 2005 and 2014. Second, using the national 5{\%} Medicare database, we examined 253 men, aged ≥66 years, with COPD who initiated TRT between 2008 and 2013. We used difference-in-differences (DID) statistical modeling to compare pre- versus post-respiratory hospitalization rates in TRT users versus matched TRT nonusers over a parallel time period. DID analyses showed that TRT users had a greater relative decrease in respiratory hospitalizations compared with nonusers. Specifically, middle-aged TRT users had a 4.2{\%} greater decrease in respiratory hospitalizations compared with nonusers (-2.4 decrease vs. 1.8 increase; p = 0.03); and older TRT users had a 9.1{\%} greater decrease in respiratory hospitalizations compared with nonusers (-0.8 decrease vs. 8.3 increase; p = 0.04). These findings suggest that TRT may slow disease progression in patients with COPD. Future studies should examine this association in larger cohorts of patients, with particular attention to specific biological pathways.",
keywords = "androgen therapy, chronic obstructive pulmonary disease, hospitalization, Testosterone replacement therapy",
author = "Jacques Baillargeon and Randall Urban and Wei Zhang and Zaiden, {Mohammed Fathi} and Zulqarnain Javed and Melinda Sheffield-Moore and Kuo, {Yong Fang} and Gulshan Sharma",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1479972318793004",
language = "English (US)",
volume = "16",
journal = "Chronic Respiratory Disease",
issn = "1479-9723",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Testosterone replacement therapy and hospitalization rates in men with COPD

AU - Baillargeon, Jacques

AU - Urban, Randall

AU - Zhang, Wei

AU - Zaiden, Mohammed Fathi

AU - Javed, Zulqarnain

AU - Sheffield-Moore, Melinda

AU - Kuo, Yong Fang

AU - Sharma, Gulshan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Testosterone deficiency is common in men with chronic obstructive pulmonary disease (COPD) and may exacerbate their condition. Research suggests that testosterone replacement therapy (TRT) may have a beneficial effect on respiratory outcomes in men with COPD. To date, however, no large-scale nationally representative studies have examined this association. The objective of the study was to assess whether TRT reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD. We conducted two retrospective cohort studies. First, using the Clinformatics Data Mart-a database of one of the largest commercially insured populations in the United States-we examined 450 men, aged 40-63 years, with COPD who initiated TRT between 2005 and 2014. Second, using the national 5% Medicare database, we examined 253 men, aged ≥66 years, with COPD who initiated TRT between 2008 and 2013. We used difference-in-differences (DID) statistical modeling to compare pre- versus post-respiratory hospitalization rates in TRT users versus matched TRT nonusers over a parallel time period. DID analyses showed that TRT users had a greater relative decrease in respiratory hospitalizations compared with nonusers. Specifically, middle-aged TRT users had a 4.2% greater decrease in respiratory hospitalizations compared with nonusers (-2.4 decrease vs. 1.8 increase; p = 0.03); and older TRT users had a 9.1% greater decrease in respiratory hospitalizations compared with nonusers (-0.8 decrease vs. 8.3 increase; p = 0.04). These findings suggest that TRT may slow disease progression in patients with COPD. Future studies should examine this association in larger cohorts of patients, with particular attention to specific biological pathways.

AB - Testosterone deficiency is common in men with chronic obstructive pulmonary disease (COPD) and may exacerbate their condition. Research suggests that testosterone replacement therapy (TRT) may have a beneficial effect on respiratory outcomes in men with COPD. To date, however, no large-scale nationally representative studies have examined this association. The objective of the study was to assess whether TRT reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD. We conducted two retrospective cohort studies. First, using the Clinformatics Data Mart-a database of one of the largest commercially insured populations in the United States-we examined 450 men, aged 40-63 years, with COPD who initiated TRT between 2005 and 2014. Second, using the national 5% Medicare database, we examined 253 men, aged ≥66 years, with COPD who initiated TRT between 2008 and 2013. We used difference-in-differences (DID) statistical modeling to compare pre- versus post-respiratory hospitalization rates in TRT users versus matched TRT nonusers over a parallel time period. DID analyses showed that TRT users had a greater relative decrease in respiratory hospitalizations compared with nonusers. Specifically, middle-aged TRT users had a 4.2% greater decrease in respiratory hospitalizations compared with nonusers (-2.4 decrease vs. 1.8 increase; p = 0.03); and older TRT users had a 9.1% greater decrease in respiratory hospitalizations compared with nonusers (-0.8 decrease vs. 8.3 increase; p = 0.04). These findings suggest that TRT may slow disease progression in patients with COPD. Future studies should examine this association in larger cohorts of patients, with particular attention to specific biological pathways.

KW - androgen therapy

KW - chronic obstructive pulmonary disease

KW - hospitalization

KW - Testosterone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=85056653842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056653842&partnerID=8YFLogxK

U2 - 10.1177/1479972318793004

DO - 10.1177/1479972318793004

M3 - Article

VL - 16

JO - Chronic Respiratory Disease

T2 - Chronic Respiratory Disease

JF - Chronic Respiratory Disease

SN - 1479-9723

ER -